

iMig2023

LILLE GRAND PALAIS
FRANCE • JUNE 26→28

PROGRAM



www.iMig2023.org

#iMig2023

Dear Colleagues,

On behalf of the International Mesothelioma Interest Group (iMig) and the French Cooperative Thoracic Intergroup (IFCT), it is a great pleasure and an honour to extend you a warm invitation to join us for the 16th International Conference of the international Mesothelioma interest group (iMig 2023) to be held on June 26th – 28th 2023 in Lille, France.

Building on the experience and the success of previous great meetings since the founding of iMig in Paris in 1991 our multidisciplinary conference will bring together delegates from around the world and feature the most up-to-date research on diverse topics of interest.

Through workshops, plenary sessions, oral abstracts, poster sessions, and other events, this meeting will offer you plenty of networking opportunities with leading scientists and researchers, and also with patients and their associations. The resulting stimulating ideas will help to establish research collaborations and to fund projects.

We are very proud and excited to host the iMig Conference in France again at the beginning of summer 2023 in Lille, a modern city with friendly and beautiful traditions.

It is an exciting time for mesothelioma research and management, and we hope you will be able to join us for this outstanding scientific event.

We look forward to seeing you at iMig 2023!

Pr Arnaud Scherpereel, iMig 2023 Conference Chair, iMig President

Pr Jan van Meerbeeck, iMig 2023 Conference Co-Chair

Pr Virginie Westeel, IFCT President



Sunday, June 25, 2023

11:30am-5:45pm | iMig/ITONF MESO NURSE MEETING

— 11:30am-3:05pm | **PLENARY SESSION 1** | INSTITUT COEUR POUMON

Working towards a greater understanding through rigorous research

Chairs: Liz DARLISON, UK & Melissa CULLIGAN, USA

11:30am > 12:15pm

Tour of hospital - CHU de Lille & Institut Coeur Poumon.

12:15pm > 1:00pm

Registration, lunch, exhibition & poster viewing.

1:00pm > 1:05pm

Opening & welcome to ITONF / iMig nursing workshop.

Arnaud SCHERPEREEL, France

1:05pm > 1:30pm

The story of a dedicated research team in Mesothelioma.

Angela TOD, UK

1:30pm > 1:50pm

Surviving Mesothelioma in 2023: the latest and greatest treatment options.

Suzanne WALKER, USA

1:50pm > 2:35pm

Nursing abstracts in Mesothelioma.

Discussant: Bethany TAYLOR, UK

2:35pm > 3:05pm

Afternoon tea - Meet the nurse researchers.

— 3:05pm-5:45pm | **PLENARY SESSION 2** | INSTITUT COEUR POUMON

Improving survivorship in Mesothelioma

Chairs: Liz DARLISON, UK & Melissa CULLIGAN, USA

3:05pm > 3:35pm

Cancer survivorship expert.

Erica GLASS, USA

3:35pm > 3:50pm

Long term survivorship.

Matt JOHNSON, UK

3:50pm > 4:10pm

My journey with Mesothelioma.

Gary MAXWELL, USA

4:10pm > 4:30pm

Survivorship panel discussion.

Led by Liz DARLISON, UK

4:30pm > 4:50pm

Nursing abstracts in Mesothelioma.

Led by Leah TAYLOR, UK

4:50pm > 5:00pm

Getting the most out of the iMig Conference.

Led by Melissa CULLIGAN, USA

5:00pm > 5:45pm

Summary and closing - Networking reception.

Mary DUFFY, UK

FROM 6:30pm | **WELCOME RECEPTION**

Monday, June 26, 2023

7:30am-8:30am | DELEGATES ARRIVAL

— 8:30am-10:30am | **OPENING PLENARY SESSION 1** | AMPHITHEATER

Epidemiology status and major pathogenesis breakthrough in Mesothelioma in 2023

Chairs: Françoise GALATEAU-SALLÉ, France; Jim TEWATERNAUDE, South Africa; Jan VAN MEERBEECK, Belgium

8:30am > 8:45am

Welcome speech and an overview of our lost colleagues' career in Mesothelioma.

Arnaud SCHERPEREEL and Virginie WESTEEL, France; Sam ARMATO, USA

8:45am > 9:00am

Lecture 1: The global Mesothelioma epidemic and control strategies in 2023.

Arthur L. FRANK, USA

9:00am > 9:15am

Lecture 2: Pleural and Peritoneal Mesotheliomas: two disease cousins but not sisters.

Vahan KEPENEKIAN, France

9:15am > 9:30am

Lecture 3: A general review on genomics advances - a single cell landscape of Mesothelioma.

Jennette CREANEY, Australia

9:30am > 9:45am

Lecture 4: Mesothelioma, a BAP1 story.

Raffit HASSAN, USA

9:45am > 10:30am | Overall Q&A or general discussion moderated by the session chairs

Sponsored by



10:30am-11:00am BREAK, e-POSTER VIEWING & BOOTH VISIT

—11:00am-12:45pm | **PLENARY 2** | AMPHITHEATER

Pathology classification, predictive biomarkers...: have we yet the right tools for discussing Mesothelioma cases in MTB?

Chairs: Harvey PASS, USA; Anna NOWAK, Australia; Luana CALABRO, Italy

11:00am > 11:15am

Lecture 1: New entities and concepts of the 2021 WHO classification for Mesothelioma.

Sonia KLEBE, Australia

11:15am > 11:30am

Pro/con debate: Immunotherapy is an established treatment in Pleural Mesothelioma based on clinical trials data - PRO.

Hedy KINDLER, USA

11:30am > 11:45am

Pro/con debate: Immunotherapy is an established treatment in Pleural Mesothelioma based on clinical trials data - CON.

Luciano MUTTI, Italy

11:45am > 11:55am

Lecture 4: Optimizing immunotherapy in Mesothelioma by in situ imaging: lessons from lung cancer experience

Diane DAMOTTE, France

11:55am > 12:05pm

CO-024. Computational dissection of pleural mesothelioma identifies biomarkers to distinguish malignant sarcomatoid cells from benign mesenchymal stroma. David T. SEVERSON, USA

12:05pm > 12:15pm

CO-043. Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma. Dean FENNEL, UK

12:15pm > 12:45pm | Overall Q&A or general discussion moderated by the session chairs

Sponsored by



12:45pm-1:00pm LUNCHEON BREAK | LUNCHBOXES DELIVERY FOR ALL THE DELEGATES



— 1:00pm-2:00pm | LUNCHEON BREAK IN THE ROOM

Satellite meeting for patients associations

IMIG Board meeting

2:00pm-2:15pm COFFEE BREAK



— 2:15pm-3:45pm | **WORKSHOP 1** | AMPHITHEATER

An international effort to standardize Surgery for Mesothelioma

Chairs: Joseph FRIEDBERG, USA; Nicolas VENISSAC, France; Veerle SURMONT, Belgium

2:15pm > 2:25pm

Lecture 1: Surgery for Pleural Mesothelioma - Framing the issues holding us back. Joseph FRIEDBERG, USA

2:25pm > 2:40pm

Lecture 2 : A proposed revision for pleural mesothelioma surgery nomenclature. Seiki HASEGAWA, Japan

2:40pm > 2:55pm

Lecture 3: A proposed synoptic operative reporting system for pleural Mesothelioma surgery. Valerie RUSCH, USA

2:55pm > 3:05pm

Lecture 4: Standardizing surgical techniques and reporting for the MARS2 Trial: Lessons learned and opportunities for improvement. John EDWARDS, UK

3:05pm > 3:20pm

Lecture 5: Standardization of techniques, reporting, or both - what to do and how to use this information to move the field forward? Harvey PASS, USA

3:20pm > 3:35pm

Lecture 6: Completeness of resection scoring and other tools for Peritoneal Mesothelioma – Lessons learned from 25 years that could be applied to Pleural surgery. Olivier GLEHEN, France

3:35pm > 3:45pm | Overall Q&A or general discussion moderated by the session chairs

— 2:15pm-3:45pm | **WORKSHOP 2** | ROOM ARTOIS

Focussing on patients experience: improving mesothelioma patients and relatives management

Chairs: Dan STERMAN, USA; Linda REINSTEIN, ADAO; Robert RINTOUL, UK; Philippe ASTOUL, France

2:15pm > 2:30pm

Lecture 1: Investigating suspected Mesothelioma in the frail patient. Nick MASKELL, UK

2:30pm > 2:45pm

Lecture 2: Optimal management of pleural effusion and trapped lung. Gary LEE, Australia

2:45pm > 2:55pm

CO-044. Real-world toxicity with dual immunotherapy for malignant pleural mesothelioma. Barbara PUTMAN, Belgium

2:55pm > 3:05pm

CO-055. The effect of mesothelioma on the mental health of patients and carers in the UK: A cross sectional survey. Virginia SHERBORNE, UK

3:05pm > 3:15pm

CO-054. The Asbestos-Induced Immune Microenvironment Plays a Key Role in Malignant Mesothelioma Pathogenesis and May be Exploited for Chemoprevention. Yuwaraj KADARIYA, USA

3:15pm > 3:30pm

Late breaking abstract.

3:30pm > 3:45pm | Overall Q&A or general discussion moderated by the session chairs

— 2:15pm-3:45pm | **WORKSHOP 3** | ROOM RUBENS

Imaging (AI, diagnosis, staging...)

Chairs: Sam ARMATO, USA; Isabelle OPITZ, Switzerland & Kristiaan NACKAERTS, Belgium

2:15pm > 2:30pm

Lecture 1: Best practices for clinical imaging in Mesothelioma. Sharyn KATZ, USA

2:30pm > 2:45pm

Lecture 2: Preoperative Planning: How imaging can support today? Thomas FRAUENFELDER, Switzerland

2:45pm > 2:55pm

CO-026. Quantitative ‘T’ category using MR in Malignant Pleural Mesothelioma. Ritu GILL, USA

2:55pm > 3:05pm

CO-027. Anatomical and Symptom Changes in Malignant Pleural Effusion using 4-Dimensional Magnetic Resonance Imaging. Geeshath JAYASEKERA, UK

3:05pm > 3:15pm

CO-028. Transfer learning approach in pre-treatment CT images to predict therapeutic response in advanced unresectable Malignant Pleural Mesothelioma. Annamaria CATINO, Italy

3:15pm > 3:30pm

Lecture 3: Establishment of a modified RECIST score for peritoneal metastases: peritoneal Mesothelioma as a model. Pascal ROUSSET, France

3:30pm > 3:45pm | Overall Q&A or general discussion moderated by the session chairs

3:45pm-4:30pm BREAK, e-POSTER VIEWING & BOOTH VISIT

— 4:30pm-6:00pm | **WORKSHOP 4** | AMPHITHEATER

From European Mesothelioma experience in to European collaborative projects initiative (iMig/ETOP joint symposium)

Chairs: Paul BAAS, The Netherlands; Ken O’BYRNE, Australia; Solange PETERS, Switzerland; Rolf STAHEL, Switzerland

4:30pm > 4:45pm

Lecture 1: From PROMISE-Meso to BEAT-Meso: the ETOP Mesothelioma trials experience. Sanjay POPAT, UK

4:45pm > 5:00pm

Lecture 2: The ETOP MESOSCAPE project: translational studies data and ongoing projects. Alessandra CURIONI-FONTECEDRO

5:00pm > 5:10pm

Lecture 3: UK research project (MIST) as a model for international initiative in Mesothelioma. Dean FENNELL, UK

5:10pm > 5:20pm

Late breaking abstract. Results of the ATOMIC-MESO Phase 3 Trial. Peter SZLOSAREK, UK

5:20pm > 5:30pm

Late breaking abstract.

5:30pm > 5:40pm

CO-006. Individualized cell-free DNA monitoring with chromosomal junctions for mesothelioma. Aaron S. MANSFIELD, USA

5:40pm > 5:50pm

CO-057. Low miR-155, -29c, -132 or -100 predicts longer survival with bevacizumab plus chemotherapy in patients with pleural mesothelioma from MAPS trial. Gérard ZALCMAN, France

5:50pm > 6:00pm | Overall Q&A or general discussion moderated by the session chairs

Sponsored by



— 4:30pm-6:00pm | **WORKSHOP 5** | ROOM ARTOIS

Pathology advances and assessment of the tumor microenvironment

Chairs: Fabien FOREST, France; Lucian R. CHIRIEAC, USA; Richard ATTANOOS, UK

4:30pm > 4:45pm

Lecture 1: State of the art of biomarkers for Immunotherapy in Mesothelioma. Sanja DACIC, USA

4:45pm > 5:00pm

Lecture 2: Separating benign from malignant lesions. Luka BRCIC, Austria

5:00pm > 5:10pm

CO-001. Prospective validation of a gene Expression Approach for the Cytological Diagnosis of Epithelioid, Biphasic Mesothelioma and Mesothelial Hyperplasia. Rossella BRUNO, Italy

5:10pm > 5:20pm

CO-029. A multicenter prospective feasibility study for definite diagnosis of malignant pleural mesothelioma by pleural effusion cytopathology. Masaki HASHIMOTO, Japan

5:20pm > 5:30pm

CO-020. Towards New Clinicopathologic Entities of Peritoneal and Pleural Neoplasms with Specific Gene Fusions. Nazim BENZERDJEB, France

5:30pm > 5:45pm

Lecture 3: Future directions and new tools in the diagnostic of Mesothelioma (AI, RNA Seq...). Sylvie LANTUEJOL, France

5:45pm > 6:00pm | Overall Q&A or general discussion moderated by the session chairs

— 4:30pm-6:00pm | **WORKSHOP 6** | ROOM RUBENS

Mesothelioma pre-clinical models and results

Chairs: Christophe BLANQUART, France; Kevin BLYTH, UK

4:30pm > 4:45pm

Lecture 1: PDX Mesothelioma models. Marc DE PERROT, Canada

4:45pm > 5:00pm

Lecture 2: Mesothelioma Explants/Organoids. Marion MACFARLANE, UK

5:00pm > 5:10pm

CO-052. Derivation and characterisation of pleural mesothelioma organoid models. Robert RINTOUL, UK

5:10pm > 5:20pm

CO-016. Mapping the Measured Metabolome to the Aberrant Genomic Landscape of Mesothelioma in Patient-Derived Cell Lines and Tumours. Michael OLANIPEKUN, UK

5:20pm > 5:30pm

CO-045. Pharmacogenomics characterization of a large collection of primary cell lines identifies novel therapeutic options for Pleural Mesothelioma. Jean Baptiste ASSIÉ, France

5:30pm > 5:40pm

CO-049. Development of new virus-like particles derived from the M13 bacteriophage for the specific transfer of cDNA in mesothelin expressing cells. Tina BRIOLAY, France

5:40pm > 6:00pm | Overall Q&A or general discussion moderated by the session chairs

— 6:00pm-6:30pm | e-POSTER MIXER & POSTER DISCUSSION SESSION

Sponsored by



Tuesday, June 27, 2023

7:30am-8:00am DELEGATES ARRIVAL

— 8:00am-9:30am | **PLENARY 3** | AMPHITHEATER

Surgery, Radiotherapy, (neo)adjuvant therapies: what is the best combo for multimodal treatment?

Chairs: Thierry BERGHMANS, Belgium; Françoise LE PIMPEC BARTHES, France; Marc DE PERROT, Canada

8:00am > 8:15am

Lecture 1 : State of surgery for pleural Mesothelioma in 2023: from prospective trials to the future. Isabelle OPITZ, Switzerland

8:15am > 8:30am

Lecture 2: Optimal integration of radiotherapy with surgery. Dirk DE RUYSSCHER, The Netherlands

8:30am > 8:45am

Lecture 3: State of the art and future direction of adjuvant therapies - preoperative, intraoperative, postoperative. Patrick FORDE, USA

8:45am > 8:55am

Lecture 4: Intrapleural CAR T therapies: a new basis for multimodal treatment? Marjorie ZAUDERER, USA

8:55am > 9:05am

CO-004. Immune response to sub-ablative radiation before extended pleurectomy-decortication in pleural mesothelioma – Results from the SMARTER trial. Marc DE PERROT, Canada

9:05am > 9:15am

Late breaking abstract. First results of the EORTC 1205 Phase 2 trial. Jo RASKIN, Belgium

9:15am > 9:30am | Overall Q&A or general discussion moderated by the session chairs

9:30am-10:15am BREAK, e-POSTER VIEWING & BOOTH VISIT

— 10:15am-11:45pm | **YOUNG INVESTIGATORS 2023** | AMPHITHEATER

Lessons and advices from previous iMig YI awardees and promising directions for Mesothelioma Research.

Chairs: Bruce ROBINSON, Australia; Najib RAHMAN, UK; Fabrice BARLESI, France

10:15am > 10:30am

Lecture 1: From previous iMig YI awardee. Anna NOWAK, Australia

10:30am > 10:45am

Lecture 2: From previous iMig YI awardee: non-invasive biomarkers (VOCs...) for Mesothelioma. Kevin LAMOTE, Belgium

10:45am > 10:55 am

CO-015. Unveiling intra-tumor heterogeneity and evolutionary processes in malignant pleural Mesothelioma at the single cell level. Matthieu FOLL, France

10:55am > 11:05am

CO-003. Deciphering dysfunctional heterogeneity of tumor-infiltrating lymphocytes from malignant pleural Mesothelioma. Katarzyna TOMCZAK, USA

11:05am > 11:15am

CO-022. Improving the response of mesothelioma to immunotherapy with targeted epigenetic editing. Kofi STEVENS, Australia

11:15am > 11:25am

CO-041. Adjuvant dendritic cell-based immunotherapy after surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal Mesothelioma. Michelle V. DIETZ, The Netherlands

11:25am > 11:45am | Overall Q&A or general discussion moderated by the session chairs

11:45am-12:00pm LUNCHEON BREAK | LUNCHBOXES DELIVERY FOR ALL THE DELEGATES



— 12:00pm-1:00pm | **INDUSTRIAL SYMPOSIUM - RS ONCOLOGY** | AMPHITHEATER

New Horizons for Cancer Therapy - Targeting Oxidative Stress Vulnerabilities

(Luncheon break in the room)



1:00pm-1:15pm COFFEE BREAK

— 1:15pm-2:45pm | **WORKSHOP 7** | AMPHITHEATER

Sponsored by



Immunotherapies: new drugs, strategies including cell therapies, and trials

Chairs: Joachim AERTS, The Netherlands; Hedy KINDLER, USA; Takashi NAKANO, Japan

1:15pm > 1:30pm

Lecture 1: CAR-T therapy from basic side and how to make them better, different targets. Astero KLAMPATSA, UK

1:30pm > 1:45pm

Lecture 2: CAR T and T Cell Receptor Constructs (TruC) for Mesothelioma - ready for prime time? Raffit HASSAN, USA

1:45pm > 1:55pm

CO-007. Chemotherapy enhances LAG-3 expressing progenitor exhausted CD8+ T cells in murine Mesothelioma that can be targeted by immune checkpoint blockade. Nicola PRINCIPE, Australia

1:55pm > 2:05pm

CO-008. PD-L1 checkpoint blockade promotes regulatory T-cell activity which underlies therapy resistance in Mesothelioma. Mandy VAN GULIJK, The Netherlands

2:05pm > 2:15pm

CO-014. Quantitative cell dynamics of macrophage-directed cytotoxicity in Mesothelioma. Malik HAMAIDIA, Belgium

2:15pm > 2:30pm

Lecture 3: A review of other current and future immunotherapy strategies. Jonathan CHEE, Australia

2:30pm > 2:45pm | Overall Q&A or general discussion moderated by the session chairs

— 1:15pm-2:45pm | **WORKSHOP 8** | ROOM ARTOIS

iMig/patients associations track: asbestos control, health promotion, advocacy, prevention and patients experience (MARF/iMig)

Chairs: Julie POWERS, USA; Harlinde DE SCHUTTER, Belgium; Jacques FAUGERON, France

1:15pm > 1:30pm

Lecture 1: A patient, family and country point of view of Mesothelioma experience. Eric JONCKHEERE, Belgium

1:30pm > 1:45pm

Lecture 2: MARF experience in health promotion, advocacy and prevention. Julie POWERS, USA (TBC)

1:45pm > 1:55pm

Lecture 3: Asbestos in India: news from the ground. Muralidhar VENKITESWARAN and Pankaja RAGHAV, India

1:55pm > 2:10pm

CO-034. Italian pool of asbestos workers cohorts: a mortality study. Daniela FERRANTE, Italy

2:10pm > 2:20pm

CO-032. Burden of malignant mesothelioma in China during 1990-2019 and projections to 2029. Tianhui CHEN, China

2:20pm > 2:30pm

CO-036. Failure of Annual Low Dose CT Scanning to Detect Early Malignant Mesothelioma in an Occupational Cohort. Steven B. MARKOWITZ, USA

2:30pm > 2:45pm | Overall Q&A or general discussion moderated by the session chairs

— 1:15pm-2:45pm | **WORKSHOP 9** | ROOM RUBENS

Peritoneal Mesothelioma

Chairs: Marcello DERACO, Italy; Olivier GLEHEN, France; Paul SUGARBAKER, USA

1:15pm > 1:30pm

Lecture 1: HIPEC, EPIC and NIPEC for peritoneal mesothelioma, what is the best cocktail? *Paul SUGARBAKER, USA*

1:30pm > 1:45pm

Lecture 2: PIPAC and PITAC to treat Mesothelioma: where are we and where do we go? *Olivia SGARBURA, France*

1:45pm > 1:55pm

CO-033. Clinicopathologic characteristics and clinical outcomes of patients with testicular Mesotheliomas.

Michael OFFIN, USA

1:55pm > 2:05pm

CO-040. Ten-year of French multicentric experience in the management of diffuse malignant peritoneal Mesothelioma with 924 patients. *Barbara NOIRET, France*

2:05pm >2:15pm

CO-039. The UK and Ireland National multi-disciplinary team meeting for peritoneal mesothelioma: optimising outcomes through better selection for surgery. *Victor KUNG, UK*

2:15pm > 2:30pm

Lecture 3: The UK Peritoneal Multi-disciplinary Team - establishing a national approach. *Tom CECIL, UK*

2:30pm > 2:45pm | Overall Q&A or general discussion moderated by the session chairs

2:45pm-3:30pm BREAK, e-POSTER VIEWING & BOOTH VISIT

— 3:30pm-5:00pm | **WORKSHOP 10** | AMPHITHEATER

Mesothelioma biology and novel targets: from bench to bedside.

Chairs: Dean FENNELL, UK; Luc WILLEMS, Belgium; Steven M. ALBELDA, USA

3:30pm > 3:45pm

Lecture 1: Induction of type 1 interferon in Mesothelioma. *Emanuela FELLEY BOSCO, Switzerland*

3:45pm > 4:00pm

Lecture 2: Targeting PRX3 as a therapeutic approach for Mesothelioma. *Brian CUNNIFF, USA*

4:00pm > 4:10pm

CO-013. Exosome-Based MiRNA Delivery for Malignant Mesothelioma Treatment. *Marco TOMASETTI, Italy*

4:10pm > 4:20pm

CO-025. Prognostic significance of EMT gene signature in Mesothelioma. *Licun WU, Canada*

4:20pm > 4:30pm

CO-012. In vitro, preclinical and patients' data evidence for a role of eosinophils in Mesothelioma response to chemotherapy. *Mégane WILLEMS, Belgium*

4:30pm > 4:40pm

CO-046. PEMbrolizumab Plus Lenvatinib In Second And Third Line Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA). *Li-Anne H. DOUMA, The Netherlands*

4:40pm > 5:00pm | Overall Q&A or general discussion moderated by the session chairs

— 3:30pm-5:00pm | **WORKSHOP 11** | ROOM ARTOIS

iMig/patients associations track: Focus on the patient experience: supportive care...

Chairs: Federica GROSSO, Italy; Laurent GREILLIER, France

3:30pm > 3:45pm

Lecture 1: Managing pain in Mesothelioma. *Pascale TOMASINI, France*

3:45pm > 4:00pm

Lecture 2: What is the optimal follow up for mesothelioma patients not having active tumor treatment? *Anna BIBBY, UK*

4:00pm > 4:10pm

CO-050. Exploring the Experiences and Coping Strategies of Individuals, Below the Age of 60, Living with Mesothelioma. *Benjamin LOND, UK*

4:10pm > 4:20pm

CO-031. Establishing the Mesothelioma UK Research Centre: co-production with patients and families.

Clare GARDINER, UK

4:20pm > 4:30pm

CO-048. Fatigue is Associated with adverse Health-related quality of life and Survival in Malignant Pleural Mesothelioma.

Mohamed RAHOUMA, Egypt

4:30pm > 4:40pm

CO-051. Cough and Mesothelioma (CAM): Emerging Themes from a qualitative study exploring the impact of cough on quality of life. *Kate SLAVEN, UK*

4:40pm > 5:00pm | Overall Q&A or general discussion moderated by the session chairs

— 3:30pm-5:00pm | **WORKSHOP 12** | ROOM RUBENS

Biomarkers, Genetics/Bioinformatics

Chairs: Michele CARBONE, USA; Didier JEAN, France

3:30pm > 3:45pm

Lecture 1: Molecular axes and specialized tumor profiles driving inter-tumor heterogeneity in Mesothelioma. *Lynnette FERNANDEZ-CUESTA, France*

3:45pm > 4:00pm

CO-047: HMGB1 serves as the key factor in the development of Mesothelioma caused by both asbestos exposure and BAP1 mutations. *Haining YANG, USA*

4:00pm > 4:10pm

CO-010. The MexTAq Collaborative Cross: Host genetics affects disease latency, but has little influence once established disease. *Scott Andrew FISHER, Australia*

4:10pm > 4:20pm

CO-005. Exploration of heterogeneity in pleural Mesothelioma primary cell lines and associated tumors at the single cell level. *Maya ARNOULD, France*

4:20pm > 4:30pm

CO-023. Spatial and temporal genomic heterogeneity of Mesothelioma. *Venkateswar ADDALA, Australia*

4:30pm > 4:45pm

CO-019. Determining the Clinical Utility of a Breath Test for Screening an Asbestos-Exposed Population for Pleural Mesothelioma: the Baseline Measurement. *Kathleen ZWIJSEN, Belgium*

4:45pm > 5:00pm | Overall Q&A or general discussion moderated by the session chairs

5:00pm-5:30pm | **e-POSTER MIXER & POSTER DISCUSSION SESSION**

Sponsored by



FROM 7:30pm | **iMig GALA DINNER - LILLE ART MUSEUM (Palais des Beaux-Arts) including iMig medals & awards announcement.**

Wednesday, June 28, 2023

8:00am-8:30am DELEGATES ARRIVAL

— 8:30am-10:00am | **PLENARY 4** | AMPHITHEATER

Not all patients die of Mesothelioma?! Exceptional survivals / cure results / perspectives

Chairs: Anne TSAO, USA; Jeremy STEELE, UK; Laurent VILLENEUVE, France

8:30am > 8:45am

Lecture 1: NCI surgical clinical trial for mesothelioma developing in carriers of germline BAP1 mutations and their affected relatives: unique clinical characteristics of these patients. *David SCHRUMP, USA*

8:45am > 9:00am

Lecture 2: BAP1 is a novel regulator of HIF-1α: clinical implications. *Michele CARBONE, USA*

9:00am > 9:10am

CO-056. Final analysis of JME-001: A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignan. *Nobukazu FUJIMOTO, Japan*

9:10am > 9:20am

Late breaking abstract. IND 227 - IFCT 1901 Phase 3 - Trial first Results. *Arnaud SCHERPEREEL, France*

9:20am > 9:30am

CO-009. Real-life efficacy of nivolumab plus ipilimumab in untreated, unresectable malignant pleural Mesotheliomas: results of French early access program. *Laurent GREILLIER, France*

9:30am > 9:45am

Lecture 3: Is it possible to be cured from a Peritoneal Mesothelioma? *Clarisse EVENO, France*

9:45am > 10:00am | Overall Q&A or general discussion moderated by the session chairs

10:00am-10:30am BREAK, e-POSTER VIEWING & BOOTH VISIT

— 10:30am-12:00pm | **WORKSHOP 13** | AMPHITHEATER

Initial localized disease, oligoprogression: ready for changes in treatment paradigm?

Chairs: Julien MAZIÈRES, France; Sjaak BURGERS, the Netherlands; Andreas RIMNER, USA and Loic LANG-LAZDUNSKI, Switzerland

10:30am > 10:45am

Lecture 1: What is oligoprogression in pleural Mesothelioma and how should we manage it? *Crispin HILEY, UK*

10:45am > 11:00am

Lecture 2: Proton therapy for localized disease. *Charles SIMONE, USA*

11:00am > 11:10am

CO-021. Less could be more – patients with over 3-year median survival show no significant difference between radical surgery and a less invasive approach. *Warren NASELSKY, USA*

11:10am > 11:20am

CO-017. Recurrence patterns after pleurectomy decortication for pleural Mesothelioma (PM). *Juuso PAAJANEN, USA*

11:20am > 11:30am

CO-002. Clinical outcomes of stereotactic body radiotherapy for Mesothelioma. *Jacob Y. SHIN, USA*

11:30am > 11:50am

Pro/Con discussion of the value of oligodisease strategies in the IO era, using clinical cases. *Andreas RIMNER, USA and Giovanni CERESOLI, Italy*

11:50am > 12:00pm | Overall Q&A or general discussion moderated by the session chairs

— 10:30am-12:00pm | **WORKSHOP 14** | ROOM ARTOIS

Nurses and allied health: advances in Mesothelioma patients care

Chairs: Liz DARLISON, UK; Melissa CULLIGAN, USA; Thierry PIETERS, Belgium

10:30am > 10:45am

Lecture 1: Integrating Palliative Care Across the Mesothelioma Patient Journey.

Sarah HARGREAVES and Bethany TAYLOR, UK

10:45am > 11:00am

Lecture 2: Equitable Access to Clincial Trials - from a National Approach to international suggestions. *Leah TAYLOR, UK*

11:00am > 11:10am

Lecture 3: Broadening the Scope of Practice for Mesothelioma Nurses - Establishing a Nurse Led Pleural Service.

Jennifer LATHAM, UK

11:10am > 11:20am

CO-035. Integrating a patient organisation for rare thoracic tumours (TUTOR) in the network of advocates for Mesothelioma patients and caregivers in Italy. *Laura ABATE-DAGA, Italy*

11:20am > 11:30am

CO-037. How can Mesothelioma Clinical Nurse Specialists optimise clinical decision making for mesothelioma patients?

Zoe DAVEY, UK

11:30am > 11:40am

CO-038. Quality-of-Life and Dyspnea Experience Before and After Lung-Sparing Surgery for Pleural Mesothelioma: A Scoping Review Using the Theory of Unpleasant. *Melissa CULLIGAN, USA*

11:40am > 12:00pm Overall Q&A or general discussion moderated by the session chairs

— 10:30am-12:00pm | **WORKSHOP 15** | ROOM RUBENS

Is Personalized Medicine ready for prime time in Mesothelioma? (genetics, targeted therapies, immunotherapies, clinical trials...)

Chairs: Gérard ZALCMAN, France; Dean FENNELL, UK or Marjorie ZAUDERER, USA

10:30am > 10:45am

Lecture 1: MTAP, NF2/YAP/TAZ/Hippo agents, and VISTA target in Mesothelioma. *Ibiayi DAGOGO-JACK, USA*

10:45am > 11:00am

Lecture 2: New biological targets for Mesothelioma. *Yoshitaka SEKIDO, Japan*

11:00am > 11:10am

CO-042. A gut microbiota rheostat forecasts response to PDL1-VEGF blockade in Mesothelioma. *Aleksandra BZURA, UK*

11:10am > 11:20am

CO-018. Diversity of tumor immune microenvironment landscape of epithelioid malignant pleural mesothelioma in patients with primary surgically resected tumors. *Katarzyna TOMCZAK, USA*

11:20am > 11:30am

CO-011. The immune response to mesothelioma is directed at a highly restricted set of tumour antigens.

Jessica BOULTER, Australia

11:30am > 11:45am

Lecture 3: An overview of the best candidate drugs and strategies for personalized Medicine in Mesothelioma.

Anne TSAO, USA

11:45am > 12:00pm | Overall Q&A or general discussion moderated by the session chairs

12:00pm-12:45pm LUNCHEON BREAK | LUNCHBOXES DELIVERY FOR ALL THE DELEGATES





— 12:45pm-2:15pm | **PLENARY 5** | AMPHITHEATER

Joint iMig/IASLC Session: Work in progress and what's next in Mesothelioma field?

Chairs: Paul BAAS, The Netherlands; Paul VAN SCHIL, Belgium; Raphael BUENO, USA

12:45pm > 1:00pm

IMIG AWARDS AND YOUNG INVESTIGATORS AWARDS

1:00pm > 1:10pm

Lecture 1: Joint IASLC/iMig initiatives in Pleural Mesothelioma field.

Paul VAN SCHIL, Belgium and Arnaud SCHERPEREEL, France

1:10pm > 1:25pm

Lecture 2: Promises and pitfalls of AI for Mesothelioma imaging? Sam ARMATO, USA

1:25pm > 2:05pm


Lecture 3: Interactive panel discussion ("MTB") about optimized management and future directions in pleural Mesothelioma management starting from clinical cases.

Bruce ROBINSON, Australia; Isabelle OPITZ, Switzerland; Dean FENNELL, UK; Aaron MANSFIELD, Anne TSAO, USA; Andreas RIMNER, USA; Melissa CULLIGAN, USA & Ken O'BYRNE, Australia

2:05pm > 2:15pm | Overall Q&A or general discussion moderated by the session chairs

2:15pm-2:30pm | **PRESIDENTIAL CLOSING & SAVE THE DATE iMig 2025**

Arnaud SCHERPEREEL and Virginie WESTEEL, France; iMig 2025 chair




Conference venues



June 26 -> 28

LILLE GRAND PALAIS

1 Boulevard des Cités Unies, Lille



Sunday, June 25
**CHU LILLE INSTITUT
COEUR POUMON**

Boulevard du Professeur
Jules Leclercq, Lille





iMig 2023 Local, Regional, National and International supports and/or endorsements



The IMIG congress is organized with the support of our partners

